| Literature DB >> 35539450 |
Rong Hu1, Yunping Zhoujin1, Meng Liu1, Mingtao Zhang2, Sean Parkin3, Panpan Zhou4, Jianzhi Wang1, Faquan Yu1, Sihui Long1.
Abstract
We report the discovery of two new forms (II and III) of a potential non-steroidal anti-inflammatory and thyroid drug, 2-((2,6-dimethylphenyl)amino)benzoic acid (HDMPA) through solution growth and thermal treatment of crystals. Form II has been discovered through crystal growth in a variety of solvents, and characterized by single-crystal X-ray diffraction, powder X-ray diffraction (PXRD), FT-IR, and Raman spectroscopy. Form II converts into form III upon thermal treatment, as indicated by the phase behavior study of form II with differential scanning calorimetry (DSC). Form III has been characterized by IR, Raman and PXRD. Conformational flexibility of the molecule seems to lead to the polymorphism of the system. A conformational scan shows the conformational minima correspond to the conformers in the polymorphs. Lattice energy calculations show energies of -48.14 and -50.31 kcal mol-1 for forms I and II, providing information on the relative stability for each form. Hirshfeld analysis revealed that intermolecular interactions such as C⋯C, H⋯H, C⋯H, and H⋯O contribute to the stability of the crystal forms. This journal is © The Royal Society of Chemistry.Entities:
Year: 2018 PMID: 35539450 PMCID: PMC9080045 DOI: 10.1039/c7ra13353g
Source DB: PubMed Journal: RSC Adv ISSN: 2046-2069 Impact factor: 4.036
Scheme 1Synthesis of HDMPA.
Crystal growth of HDMPA in different solvents
| Solvents | Method | Form |
|---|---|---|
| Acetone | Slow evaporation | II |
| Chloroform | Slow evaporation | II |
| Ethyl acetate | Slow evaporation | II |
| Methanol | Slow evaporation | II |
| Dichloromethane | Slow evaporation | II |
| Ethanol | Slow evaporation | II |
| Hexane | Slow evaporation | II |
| Pet ether | Slow evaporation | II |
| Acetonitrile | Slow evaporation | II |
| Ether | Slow evaporation | II |
| iso-Propanol | Slow evaporation | II |
| Dimethyl sulfoxide | Slow evaporation | II |
| Tetrahydrofuran | Slow evaporation | II |
| Dimethylformamide | Slow evaporation | II |
| Toluene | Slow evaporation | II |
| Benzene | Slow evaporation | II |
| Acetic acid | Slow evaporation | II |
| Tetrahydrofuran & acetone (1 : 1) | Slow evaporation | II |
| Tetrahydrofuran & acetone (various ratios) | Quench cooling | II |
Fig. 1Labeling of HDMPA.
Bond length of C1–N7 and N7–C8 in the conformers of HDMPA
| Conformer | Bond length (Å) | |
|---|---|---|
| C1–N7 | N7–C8 | |
| I-A | 1.380 | 1.432 |
| I-B | 1.363 | 1.465 |
| II (RT) | 1.375 | 1.441 |
| II (LT) | 1.378 | 1.441 |
Fig. 2SEM micrographs of crystals of HDMPA form II from different solvents and form III.
Crystallographic data of HDMPA polymorphs I and II (LT, low temperature, determined at 90 K; and RT, room temperature, determined at 296 K)
| I | II (LT) | II (RT) | |
|---|---|---|---|
| Formula | C15H15NO2 | C15H15NO2 | C15H15NO2 |
| Formula weight | 241.28 | 241.28 | 241.28 |
| Crystal size (mm) | 0.50 × 0.50 × 0.15 | 0.30 × 0.20 × 0.20 | |
| Crystal system | Triclinic | Triclinic | Triclinic |
| Space group |
|
|
|
|
| 15.8375(16) | 7.4127(1) | 7.524(2) |
|
| 7.5311(7) | 8.0298(1) | 8.103(2) |
|
| 11.1845(12) | 10.9583(2) | 11.191(3) |
|
| 83.728(9) | 73.3544(8) | 72.582(4) |
|
| 104.806(9) | 83.3366(8) | 83.740(4) |
|
| 79.038(8) | 73.6078(8) | 73.854(2) |
|
| 4, 2 | 2, 1 | 2, 1 |
|
| 1248.560 | 599.091(16) | 625.1(3) |
|
| 1.284 | 1.338 | 1.276 |
|
| 296 | 90(2) | 296(2) |
| Abs. coeff. (mm−1) | 0.089 | 0.085 | |
|
| 256 | 254 | |
| Range (deg) | 1.94–27.49 | 1.91–25.00 | |
| Limiting indices | −9 ≤ | −6 ≤ | |
| −10 ≤ | −9 ≤ | ||
| −14 ≤ | −13 ≤ | ||
| Completeness to 2 | 99.5% | 98.5% | |
| Unique reflections | 2737 | 2170 | |
|
| 0.0553 | 0.0434 | 0.0490 |
| w | 0.0553 | 0.1190 | 0.1552 |
Fig. 3Superposition of all three molecular conformations in the asymmetric units of forms I and II of HDMPA.
Fig. 4Crystal packing of I and II. For clarity, only hydrogens involved in hydrogen bonds (dotted line) are shown.
Fig. 5DSC thermograms of HDMPA form II before and after thermal treatment.
Fig. 6PXRD patterns of HDMPA form II before and after thermal treatment.
Fig. 7Experimental and calculated PXRD patterns of HDMPA polymorphs.
Fig. 8IR spectra of the new forms of HDMPA.
Characteristic IR peaks of the new forms of HDMPA
| N–H stretch | Carboxyl O–H stretch and aromatic/aliphatic C–H stretch | Carboxyl C | Aromatic C | |
|---|---|---|---|---|
| Form II | 3339.5 | 3031.7–2565.3 | 1650.8 | 1596.6 |
| 1572.9 | ||||
| 1500.1 | ||||
| Form III | 3343.3 | 3077.6–2561.0 | 1658.4 | 1595.0 |
| 1572.5 | ||||
| 1501.8 |
Fig. 9Raman spectra of HDMPA polymorphs.
Characteristic Raman peaks of the new forms of HDMPA
| N–H stretch | Carboxyl O–H stretch and aromatic/aliphatic C–H stretch | Carboxyl C | Aromatic C | |
|---|---|---|---|---|
| Form II | 3340.6 | 3090.5–2919.0 | 1621.5 | 1591.4 |
| 1578.3 | ||||
| 1401.2 | ||||
| Form III | 3343.4 | 3079.4–2919.4 | 1623.7 | 1592.5 |
| 1578.0 | ||||
| 1408.2 |
Fig. 10Conformation scan of single HDMPA molecule.
Torsion angle of the conformers
| Conformer | Torsion angle (C6–N7–C8–C9/C13) (°) |
|---|---|
| I-A | −102.32/79.77 |
| I-B | 94.88/−79.51 |
| II | 79.63/−99.50 |
Fig. 11Hirshfeld surface analysis of the two forms of HDMPA, (a) form II; and (b) form I.